Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses as NEP inhibitors for the treatment of cardiovascular diseases. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention. Particular compounds include (R)-4-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-3-(3-phosphonopropanamido)butanoic acid or a pharmaceutically acceptable salt thereof; (3-(((2R)-1-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-4-(1-(((cyclohexyloxy)carbonyl)oxy)ethoxy)-4-oxobutan-2-yl)amino)-3-oxopropyl)phosphonic acid or a pharmaceutically acceptable salt thereof; and (3-(((R)-1-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-4-((S)-1-(((cyclohexyloxy)carbonyl)oxy)ethoxy)-4-oxobutan-2-yl)amino)-3-oxopropyl)phosphonic acid or a pharmaceutically acceptable salt thereof.